Zacks Research Analysts Lower Earnings Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities researchers at Zacks Research cut their Q1 2025 EPS estimates for shares of Ironwood Pharmaceuticals in a report released on Monday, October 14th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of $0.03 for the quarter, down from their previous estimate of $0.06. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.24 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.08 EPS, Q2 2026 earnings at $0.09 EPS and FY2026 earnings at $0.40 EPS.

Several other equities analysts also recently commented on IRWD. Craig Hallum dropped their price target on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 16th. Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. Wells Fargo & Company lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Finally, Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their target price for the stock from $12.00 to $4.00 in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $12.17.

Ironwood Pharmaceuticals Stock Up 2.5 %

NASDAQ:IRWD opened at $4.50 on Wednesday. The company has a fifty day simple moving average of $4.44 and a two-hundred day simple moving average of $6.04. The company has a market cap of $704.38 million, a price-to-earnings ratio of -0.66 and a beta of 0.48. Ironwood Pharmaceuticals has a 52 week low of $3.79 and a 52 week high of $15.70.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of IRWD. Vanguard Group Inc. lifted its position in Ironwood Pharmaceuticals by 7.6% in the fourth quarter. Vanguard Group Inc. now owns 16,033,545 shares of the biotechnology company’s stock valued at $183,424,000 after acquiring an additional 1,137,845 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Ironwood Pharmaceuticals by 152.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 4,383 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 2,645 shares in the last quarter. Los Angeles Capital Management LLC raised its holdings in Ironwood Pharmaceuticals by 209.9% during the first quarter. Los Angeles Capital Management LLC now owns 85,343 shares of the biotechnology company’s stock worth $743,000 after purchasing an additional 57,806 shares in the last quarter. Hodges Capital Management Inc. purchased a new position in Ironwood Pharmaceuticals during the first quarter worth about $7,521,000. Finally, Allspring Global Investments Holdings LLC raised its holdings in Ironwood Pharmaceuticals by 63.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 79,361 shares of the biotechnology company’s stock worth $691,000 after purchasing an additional 30,745 shares in the last quarter.

Insider Activity at Ironwood Pharmaceuticals

In related news, insider Minardo John sold 9,910 shares of the business’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the completion of the sale, the insider now directly owns 284,661 shares of the company’s stock, valued at $1,215,502.47. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 12.90% of the stock is owned by corporate insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.